Oh nee joh, ik houd wel van dit soort gokjes, en degiro vraag 93 cent voor 100 aandelen als kosten dus prima te overzien. Ben nu het jaarverslag aan het doorspitten en pag. 26 vat het wel mooi samen. Als je doorleest zie je wel in hoeverre ze zelf twijfelen.
We expect to continue to incur substantial and increased expenses as we continue to pursue full commercialization of ANJESO, expand our research and development activities and advance our clinical programs for our product candidates. The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to generate revenues. Our ability to generate future revenues depends heavily on our success in:
• commercializing ANJESO;
• maintaining a sufficient commercial organization capable of sales, marketing and distribution for ANJESO or an acquired or in-licensed new product
• maintaining a commercially viable price for ANJESO;
• manufacturing commercial quantities of ANJESO at acceptable cost levels;
• effectively managing the levels of production, distribution and delivery of ANJESO through our supply chain and adequately adjusting such
production and delivery to correspond to market demand;
• obtaining coverage and adequate reimbursement from third-parties, including government payers;
• identifying and completing the acquisition or in-licensing of other commercial or near-commercial products;
• obtaining and maintaining patent protection for our product candidates; and
• completing the clinical development of our product candidates.